

CURRICULUM VITAE

STELLA T. GABETA, MD, PhD

LARISSA, MARCH 2021

PERSONAL INFORMATION

First Name: Stella
Surname: Gabeta
Father's Name: Tilemachos
Place of birth: Larissa, Greece
Date of birth: October 12, 1979
Citizenship: Greek
Profession: Internist
Marital status: Married, mother two
Telephone: 2413502886, 2413502884
e-mail: s_gampeta@yahoo.com & sgampeta@med.uth.gr
Languages: Greek, English
Current position Consultant in Internal Medicine, Department of Internal Medicine, National Expertise Centre for Autoimmune Liver Disease, University Hospital of Larissa, Greece (Director: Prof. G.N.Dalekos)

EDUCATION

17/07/2003 **Degree (ptychio) in Medicine, Hellenic Republic, University of Thessaly, Faculty of Health Sciences, Larissa Medical School, Greece.**

21/07/2003 **License to Practice Medicine**, Ref. No: 2438. Hellenic Republic, Region of Thessaly, Prefect of Larisa, Prefectural Authority of Larisa, Directorate of Hygiene, Department of Health Professions, Greece.

1/10/2012 **License to use a medical specialty qualification in Internal Medicine**, Ref. No: 4829. Hellenic Republic, Region of Thessaly, General Directorate Public Health and Social Care, Directorate of

Public Health, Department of Health Services and Professions, Greece.

20/12/2017

PhD – University of Thessaly, Faculty of Health Sciences, Larissa Medical School, Greece.

Thesis entitled “Ro-52 epitope mapping in anti-SLA/LP-positive and -negative patients with autoimmune hepatitis”.

PROFESSIONAL EXPERIENCE

Mar 2017- now Consultant in Internal Medicine, Department of Internal Medicine, National Expertise Centre for Autoimmune Liver Disease, University Hospital of Larissa, Greece (Director: Prof. G.N.Dalekos).

Oct 2015 – Aug 2017: Honorary Clinical & Research Fellow, Division of Transplantation, Immunology and Mucosal Biology, Faculty of Life Sciences and Medicine, King’s College Hospital London (Director: Professor M.A.Heneghan).

Dec 2007 – Oct 2012: Resident in Internal Medicine, Department of Medicine, University Hospital of Larissa, Greece (Director: Professor N. Stathakis up to July 2008 and then Professor G.N Dalekos).

Aug 2004 – Feb 2013: Research Fellow, Department of Medicine, Academic Liver Unit and Research Lab of Internal Medicine, Larissa Medical School, Faculty of Health Sciences, University of Thessaly, Greece (Directors: Professor N. Stathakis until Aug 2008 and then Professor G.N. Dalekos).

- Jan 2013 – Jul 2015: Training in management and treatment of patients with chronic liver diseases in the Outpatient clinic, Liver Unit, University Hospital of Larissa, Greece (Director: Professor G.N.Dalekos).
- 10/02/2004 – 10/02/2005 Obligatory medical service in rural area (Health Center of Elassona, Larissa).
- 23/10/2003- 22/01/2004 Specialty Training post for three months Clinical Rotation in the Outpatient Clinic and Emergency Departments of Medicine, Cardiology and General Surgery at the Larissa Regional General Hospital.

MEMBER OF SOCIETIES

- Hellenic Society of Internal Medicine of Northern Greece (2012)
- Hellenic Professional Union of Internists (2014)
- Hellenic Association for the Study of the Liver (2015)
- European Association for the Study of Liver (2019)

AWARDS

Scholarship by the Hellenic Association for the Study of Liver for the “Study of Autoimmune Liver Diseases” at the Division of Transplantation, Immunology and Mucosal Biology, Faculty of Life Sciences and Medicine, King’s College Hospital London (Director: Professor M.A.Heneghan). (2015)

Scholarship by the Institution of Biomedical Research and Technology (Center for Research and Technology, Thessaly- CE.RE.TE.TH, Greece) for the “Study of immunological markers in chronic liver disease”. (2007)

LANGUAGES

Greek (native)

English (Certificate of Proficiency in English, University of Cambridge, 1994 - Certificate of Proficiency in English, Michigan University, 1995 – IELTS (band 8), July 2015).

OTHER ACTIVITIES

1. **Teaching** Clinical skills in Internal Medicine in 3rd year Medical Students of the University of Thessaly, University Hospital of Larissa (academic years: 2017-2018, 2018-2019, 2019-2021 and 2020-2021).
2. Attended the 8th School of Clinical Hepatology, organized by the Hellenic Association for the Study of the Liver (**October 2014-May 2015**). Completion of exams: June 2015.
3. **Participant investigator** in a multicenter cross-sectional or longitudinal survey/study dealing with the variation of immune system markers during the transition from sepsis to severe sepsis and septic shock (**Nov 2009 – Nov 2011**).
4. **Participant sub-investigator** in a study entitled: “A phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs telaprevir, both in combination with Peg-IFN α -2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFN α and ribavirin therapy” (TMC435HPC3001) (**June 2012 – February 2013**).
5. **Participant sub-investigator** in a study entitled: “Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C” (MV25599) (**June 2012 – February 2013**).
6. **Participant sub-investigator** in a study entitled: “An international, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics” (MV25600) (**June 2012 – February 2013**).

7. **Teaching** students of Institute of Vocational Training, 2nd IEK Larissa (October 2006- June 2007).
8. **Teaching** students of Institute of Vocational Training, OAED (Manpower Employment Organization) IEK Larissa (October 2006- June 2007).
9. Attended the program of Pediatric Clinic, Huddinge Universitetssjukhus, Sweden (Director AnnBritt Bohlin), within the framework of an exchange program of the International Federation of Medical Students' Association (30 Jul 2001- 30 Aug 2001).

PAPERS IN INTERNATIONAL JOURNALS

1. A.G Kaditis, J Finder, E.I Alexopoulos, K Starantzis, K Tanou, **S Gampeta**, E Agorogiannis, S Christodoulou, A Pantazidou, K Gourgoulianis, P.A Molyvdas. Sleep disordered breathing in 3,680 Greek children. *Pediatr Pulmonol*. 2004 Jun;37(6):499-509.
2. K Zachou, C Liaskos, E Rigopoulou, **S Gabeta**, P Papamichalis, N Gatselis, S Georgiadou, G.N Dalekos. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. *Clin Immunol* 119:203-212, 2006.
3. **S Gabeta**, G.L Norman, C Liascos, P.A Papamichalis, T Zografos, A Garagunis, E.I Rigopoulou, G.N Dalekos. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgG and IgA antimitochondrial antibodies in primary biliary cirrhosis. *J Clin Immunol* 2007 Jul;27(4):378-87.
4. P.A Papamichalis, K Zachou, G.K Koukoulis, A Veloni, E.G Karakosta, L Kypri, I Mamaloudis, **S Gabeta**, E.I Rigopoulou, A.W Lohse, G.N Dalekos. The revised autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver diseases. *J Autoimmune Dis*. 2007 Jun 29;4:3.
5. **S. Gabeta**, G.L. Norman, N.Gatselis, C Liaskos, P.A Papamichalis, A Garagunis, K Zachou, E.I Rigopoulou, G.N Dalekos. IgA Anti-b2GPI

Antibodies in Patients with Autoimmune Liver Diseases. *J Clin Immunol* 28(5):501-511, 2008.

6. S.P Georgiadou, K Zachou, C Liaskos, **S Gabeta**, E.I Rigopoulou, G.N Dalekos. Occult hepatitis B virus infection in patients with autoimmune liver diseases. *Liver Int.* 2009 Mar;29(3):434-42.
7. N.K Gatselis, K Zachou, P Papamichalis, G.K Koukoulis, **S Gabeta**, G.N Dalekos, E.I Rigopoulou. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score? *Dig Liver Dis.* 2010 Nov;42(11):807-12
8. C.K Argyraki, **S Gabeta**, K Zachou, M Boulbou, A Polyzos, G.N Dalekos. Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions. *Eur J Intern Med.* 2011 Dec;22(6):e155-7.
9. N.K Gatselis, K Zachou, G.L Norman, G Tzellas, M Speletas, **S Gabeta**, A Germenis, G.K Koukoulis, G.N Dalekos. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. *Clin Chim Acta.* 2012 May 26.
10. TA Zografos, N Gatselis, K Zachou, C Liaskos, **S Gabeta**, GK Koukoulis, GN Dalekos. Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. *World J Gastroenterol.* 2012 Sep 14;18(34):4721-8.
11. N.K Gatselis, K Zachou, G.L Norman, **S Gabeta**, P Papamichalis, G.K Koukoulis, G. N Dalekos. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013 Nov;46(7):471-9.
12. K Zachou, A Sarantopoulos, N.K Gatselis, T Vassiliadis, **S Gabeta**, A Stefos, A Saitis, P Boura, G.N Dalekos. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. *World J Hepatol.* 2013 Jul 27;5(7):387-92.

13. K Zachou, **S Gampeta**, N.K Gatselis, K Oikonomou, J Goulis, MN Manoussakis, Y Renaudineau, DP Bogdanos, G.N Dalekos. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. *Liver Int.* 2015 Feb;35(2):660-72.
14. A Lyberopoulou, G Chachami, NK Gatselis, E Kyrtzopoulou, A Saitis, **S Gabeta**, P Eliades, E Paraskeva, K Zachou, GK Koukoulis, A Mamalaki, GN Dalekos, G Simos. Low Serum Hepcidin in Patients with Autoimmune Liver Diseases. *PLoS One.* 2015 Aug 13;10(8):e0135486.
15. K Zachou, NK Gatselis, P Arvaniti, **S Gabeta**, EI Rigopoulou, GK Koukoulis, GN Dalekos. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. *Aliment Pharmacol Ther.* 2016 May;43(10):1035-47.
16. **S Gabeta**, GW Wong, MA Heneghan. Liver disease in pregnancy: Beyond the guidelines. *Am J Gastroenterol.* 2016 Jul;111(7):1042-3.
17. K Zachou, **S Gabeta**, Z Shums, NK Gatselis, GK Koukoulis, GL Norman, GN Dalekos. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. *Eur J Intern Med.* 2017 Mar;38:83-88.
18. K Zachou, **S Gabeta**, NK Gatselis, GL Norman, GN Dalekos. Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late? *Eur J Intern Med* 2017 Sep;43:e48-e49.
19. TY Lim, E Gonsalkorala, MD Cannon, **S Gabeta**, L Penna, ND Heaton, MA Heneghan. Successful pregnancy outcomes following liver transplantation is predicted by renal function. *Liver Transpl.* 2018 May;24(5):606-615.
20. P Arvaniti, G Giannoulis, **S Gabeta**, K Zachou, GK Koukoulis, GN Dalekos. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. *JHEP Rep.* 2020 May 29;2(4):100123.
21. NK Gatselis, T Tornai, Z Shums, K Zachou, A Saitis, **S Gabeta**, R Albesa, GL Norman, M Papp, GN Dalekos. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. *World J Gastroenterol.* 2020 Sep 14;26(34):5130-5145.

22. K Azariadis, G Giannoulis, **S Gabeta**, A Michail, K Zachou, GN Dalekos. Severe Pharyngodynia Followed by Migratory Polyarthritis and High Fever in Young Immigrants: Remember That Rheumatic Fever Is Still Relevant in 2020! *Case Rep Infect Dis.* 2020 Nov 4;2020:8854868.
23. M Tampaki, NK Gatselis, S Savvanis, E Koullias, A Saitis, **S Gabeta**, M Deutsch, E Manesis, GN Dalekos, J Koskinas. Wilson disease: 30-year data on epidemiology, clinical presentation, treatment modalities and disease outcomes from two tertiary Greek centers. *Eur J Gastroenterol Hepatol.* 2020 Dec;32(12):1545-1552.
24. GN Dalekos, A Stefos, S Georgiadou, V Lygoura, A Michail, G Ntaios, A Samakidou, G Giannoulis, **S Gabeta**, M Vlychou, E Petinaki, K Leventogiannis, EJ Giamarellos-Bourboulis, NK Gatselis. Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. *Eur J Intern Med.* 2021 Mar 26:S0953-6205(21)00090-X.